# Exploring Peptides for Amyotrophic Lateral Sclerosis (ALS): Clinical Evidence and Anecdotal Use

Canonical source: https://retacompare.com/research/top-peptides-studied-or-used-for-amyotrophic-lateral-sclerosis-als

Peptides for Disease — Top Peptides · 2026-05-03


    This article reviews peptides studied for Amyotrophic Lateral Sclerosis (ALS), highlighting those with clinical evidence, ongoing trials, and anecdotal community reports, including Semaglutide and IGF-1 analogs, while emphasizing the distinction between research and self-reported experiences.

The big picture

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease affecting motor neurons in the brain and spinal cord, leading to muscle weakness and atrophy. The exact cause of ALS remains largely unknown, and the search for effective treatments continues. Various peptides have emerged in research and anecdotal contexts, with interest in their potential roles in managing ALS symptoms or slowing disease progression. This article aims to categorize these peptides based on their clinical evidence, ongoing research, and anecdotal reports from the community. For broader context, see the broader research library and our peptide stacking guide.

What the clinical evidence shows

Currently, there are limited FDA-approved peptides for ALS, with most research focusing on preclinical and early-phase studies. One peptide of interest is Semaglutide, a GLP-1 analog primarily used for diabetes and weight management, which is being studied for its neuroprotective effects in ALS. Preliminary data suggests that GLP-1 receptor agonists may have a positive impact on neuronal survival and function, but definitive clinical trial results are still pending.

Another area of investigation includes IGF-1 analogs, which have shown potential in enhancing motor neuron survival and function in preclinical models. However, robust clinical evidence in ALS patients remains scarce. Research continues to explore the neuroprotective properties of IGF-1 and its analogs, but as of now, no conclusive data supports their use in clinical practice for ALS.

What the community reports anecdotally

Anecdotal reports from the biohacker community and forums suggest that some individuals with ALS have experimented with peptides such as Cerebrolysin, which is approved in various countries for cognitive disorders but not in the United States. Users report varying degrees of subjective improvement in cognitive and motor functions, but these claims are entirely anecdotal and lack controlled clinical validation. Additionally, peptides like BPC-157 and TB-500 are frequently discussed in online communities for their purported regenerative properties, but again, these claims are not substantiated by scientific evidence.

Key points at a glance

ALS is a progressive neurodegenerative disease with no known cure.

Semaglutide is being studied for its potential neuroprotective effects in ALS.

IGF-1 analogs show promise in preclinical studies but lack robust clinical evidence.

Cerebrolysin has anecdotal support but is not FDA-approved for ALS in the US.

Many peptides discussed in the community are not FDA-approved for any indication.

Anecdotal reports should not be considered clinical evidence.

Research into peptides for ALS is ongoing, with many questions remaining unanswered.

Safety and what to watch for

As most peptides discussed for ALS are not FDA-approved, their safety profiles are often not well-established. Users should be aware of potential side effects and the risks associated with unregulated use. Off-label use of peptides can lead to adverse effects, and individuals should consult a healthcare professional before considering any peptide therapy.

Open questions

Despite ongoing research, many questions remain regarding the efficacy and safety of peptides in ALS treatment. Future studies are needed to determine the clinical relevance of peptides like Semaglutide and IGF-1 analogs. Regulatory uncertainties also persist, as many peptides are not approved for use in the United States, complicating access for patients seeking alternative treatment options.

Bottom line

While peptides are being explored for their potential roles in ALS management, most are not FDA-approved, and clinical evidence is limited. Anecdotal reports from the community should be interpreted with caution, as they do not replace rigorous scientific validation.

This article is research-only educational content and is not medical advice. Many of the peptides discussed are not FDA-approved for Amyotrophic Lateral Sclerosis (ALS) or any indication. Do not start or change therapy without consulting a qualified clinician.

## Sources